Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study
Korean Journal of Clinical Pharmacy
;
: 133-137, 2019.
Artigo
em Coreano
| WPRIM
| ID: wpr-759613
ABSTRACT
Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have experienced visual field defect, which recovered after drug discontinuation. She had never experienced this symptom before, and several studies have reported an association between use of statins and visual disorders such as blurred vision, diplopia, and cataract. Blockage of cholesterol accumulation, oxidative stress, or myopathy is expected to be a cause of this symptom. Naranjo scale, Korean causality assessment algorithm (Ver.2), and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were the three tools used to determine causality between the visual disorder and atorvastatin. The results represent ‘probable’, ‘certain’, and ‘probable/likely’ causality, respectively. Our results, in combination with a review of literature, indicate that ocular adverse effects are highly likely related to atorvastatin.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Farmácias
/
Transtornos da Visão
/
Catarata
/
Campos Visuais
/
Colesterol
/
Saúde Global
/
Estresse Oxidativo
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Diplopia
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Limite:
Idoso
/
Feminino
/
Humanos
País/Região como assunto:
Ásia
Idioma:
Coreano
Revista:
Korean Journal of Clinical Pharmacy
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS